GenProbe (GPRO) Sells Off After ThermoFisher (TMO) Announces Phadia Buyout
But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company for $3.5B in cash. Phadia...
GenProbe (GPRO) up 8%+on Buy-Out Rumors
Speculation chat is driving up shares of GenProbe (GPRO) on heavier volume of 2.5M shares. Two stories are notable one from the Wall Street Journal on ThermoFisher (TMO) a potential bidder, but also interested in Phadia AB an allergy testing Co., and the other on a collaboration between...
Metrics of Pure Play Diagnostic Companies: Comparison to GenProbe
M&A Premium of Diagnostic Companies Bloomberg reported on April 29 that GenProbe (GPRO) was seeking a buyer. We reported earlier this month on the M&A trend in biotechnology, tools and diagnostics and we will begin following the sector looking for value and potential buy-out targets....
Big Sell-Off in Oil, Gas and Other Commodities Spooks the Market
Relative Safety in Healthcare Stocks Today's sell-off in the energy complex with the back-drop of a U.S. slow growth scenario plus the Euro being vulnerable due to Greece and Ireland has spooked the overall market. All the major indices are down over 1% with the S&P down 1.22%. Nasdaq is...
Life Science Stocks Capture M&A Premium
Deals Are Bullish for the Market Yesterday's Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for the current M&A activity is: technologies and pipeline fit strategically, money is cheap,...